FAIRFIELD, Conn., June 28, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) today announced that the U.S. sales force for its Calmare® Pain Therapy Treatment has expanded to include 35 individuals, forming a nationwide cadre of independent sales representatives who are aggressively selling the non-invasive Calmare Pain Therapy to physicians throughout the U.S. Calmare Pain Therapy successfully treats chronic neuropathic and oncologic pain resulting from cancer, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies.
"We have seen increased interest in our Calmare Pain Therapy Treatment following our medical conference in Boston last month and the presentations highlighting Calmare's efficacy in treating cancer-related pain at this month's American Society of Clinical Oncology (ASCO) Annual Meeting," said John B. Nano, CTT's Chairman, President and CEO. "Our expanded U.S. sales team is introducing our innovative pain treatment to physicians and medical professionals nationwide. Combined with our international distributors covering half the world's population, we are creating a paradigm shift in how chronic pain is treated globally. I firmly expect our revenue from sales of the Calmare device to grow more rapidly as doctors and their patients observe the growing body of evidence-based patient outcomes that shows Calmare successfully treats various types of oncologic and neuropathic pain suffered by millions of patients worldwide, including 75 million Americans who suffer from chronic pain."
"We are excited to be bringing sales leaders from the medical device industry to our team to drive revenue from our Calmare Pain Therapy Treatment, following the positive reception of the evidence-based research presented at the ASCO meeting earlier this month," said John Rooney, CTT's Vice President, U.S. Sales and Marketing. "Being able to offer physicians a non-invasive, effective method for treating chronic pain without the harmful, adverse side effects of opioids such as morphine is a key focus of our mission to improve the quality of life for patients suffering from debilitating oncologic and neuropathic pain."
Calmare is being used to treat pain patients at universities including Virginia Commonwealth University's Massey Cancer Center, under the direction of Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit; the University of Wisconsin, Madison's Paul Carbone Cancer Center under the direction of Toby Campbell, M.D.; and the University of Miami's Pain Management Center, under the direction of Salahadin Abdi, MD, PhD, Professor and Chief, University of Miami Pain Management Center. Additionally, patients are being treated with Calmare at hospitals and clinics in Massachusetts, New York, Virginia, Florida, Connecticut, Rhode Island, and Utah, as well as in Europe and Asia.
The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is currently manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales. For more information about Calmare Pain Therapy Treatment, visit www.CalmareTT.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.